208 related articles for article (PubMed ID: 32521162)
21. JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice.
Song X; Zhu S; Xie Y; Liu J; Sun L; Zeng D; Wang P; Ma X; Kroemer G; Bartlett DL; Billiar TR; Lotze MT; Zeh HJ; Kang R; Tang D
Gastroenterology; 2018 Apr; 154(5):1480-1493. PubMed ID: 29248440
[TBL] [Abstract][Full Text] [Related]
22. Collagenase Nanoparticles Enhance the Penetration of Drugs into Pancreatic Tumors.
Zinger A; Koren L; Adir O; Poley M; Alyan M; Yaari Z; Noor N; Krinsky N; Simon A; Gibori H; Krayem M; Mumblat Y; Kasten S; Ofir S; Fridman E; Milman N; Lübtow MM; Liba L; Shklover J; Shainsky-Roitman J; Binenbaum Y; Hershkovitz D; Gil Z; Dvir T; Luxenhofer R; Satchi-Fainaro R; Schroeder A
ACS Nano; 2019 Oct; 13(10):11008-11021. PubMed ID: 31503443
[TBL] [Abstract][Full Text] [Related]
23. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.
Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T
Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134
[TBL] [Abstract][Full Text] [Related]
24. Diphenylbutylpiperidine Antipsychotic Drugs Inhibit Prolactin Receptor Signaling to Reduce Growth of Pancreatic Ductal Adenocarcinoma in Mice.
Dandawate P; Kaushik G; Ghosh C; Standing D; Ali Sayed AA; Choudhury S; Subramaniam D; Manzardo A; Banerjee T; Santra S; Ramamoorthy P; Butler M; Padhye SB; Baranda J; Kasi A; Sun W; Tawfik O; Coppola D; Malafa M; Umar S; Soares MJ; Saha S; Weir SJ; Dhar A; Jensen RA; Thomas SM; Anant S
Gastroenterology; 2020 Apr; 158(5):1433-1449.e27. PubMed ID: 31786131
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia-activated prodrugs in the treatment of advanced pancreatic adenocarcinoma.
Babiker HM; Riaz IB; Shah SR; Von Hoff DD; Borad MJ
Anticancer Drugs; 2017 Feb; 28(2):127-132. PubMed ID: 27685167
[TBL] [Abstract][Full Text] [Related]
26. Antihypertension Nanoblockers Increase Intratumoral Perfusion of Sequential Cytotoxic Nanoparticles to Enhance Chemotherapy Efficacy against Pancreatic Cancer.
Bian S; Dong H; Zhao L; Li Z; Chen J; Zhu X; Qiu N; Jia X; Song W; Li Z; Zheng S; Wang H; Song P
Adv Sci (Weinh); 2022 Oct; 9(29):e2201931. PubMed ID: 36026578
[TBL] [Abstract][Full Text] [Related]
27. Efficacious delivery of protein drugs to prostate cancer cells by PSMA-targeted pH-responsive chimaeric polymersomes.
Li X; Yang W; Zou Y; Meng F; Deng C; Zhong Z
J Control Release; 2015 Dec; 220(Pt B):704-14. PubMed ID: 26348387
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia and pancreatic ductal adenocarcinoma.
Yamasaki A; Yanai K; Onishi H
Cancer Lett; 2020 Aug; 484():9-15. PubMed ID: 32380129
[TBL] [Abstract][Full Text] [Related]
29. A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts.
Kawakami K; Hattori M; Inoue T; Maruyama Y; Ohkanda J; Kato N; Tongu M; Yamada T; Akimoto M; Takenaga K; Sassa T; Suzumiy J; Honma Y
Anticancer Agents Med Chem; 2012 Sep; 12(7):791-800. PubMed ID: 22263802
[TBL] [Abstract][Full Text] [Related]
30. Tumor Priming by SMO Inhibition Enhances Antibody Delivery and Efficacy in a Pancreatic Ductal Adenocarcinoma Model.
Wang J; Chan DKW; Sen A; Ma WW; Straubinger RM
Mol Cancer Ther; 2019 Nov; 18(11):2074-2084. PubMed ID: 31363010
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
[TBL] [Abstract][Full Text] [Related]
32. FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
Mohamed AA; Thomsen A; Follo M; Zamboglou C; Bronsert P; Mostafa H; Amen A; Mekawy M; Grosu AL; Brunner TB
Strahlenther Onkol; 2021 Jan; 197(1):27-38. PubMed ID: 32705304
[TBL] [Abstract][Full Text] [Related]
33. Hypoxia induces TWIST-activated epithelial-mesenchymal transition and proliferation of pancreatic cancer cells in vitro and in nude mice.
Chen S; Chen JZ; Zhang JQ; Chen HX; Yan ML; Huang L; Tian YF; Chen YL; Wang YD
Cancer Lett; 2016 Dec; 383(1):73-84. PubMed ID: 27693633
[TBL] [Abstract][Full Text] [Related]
34. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis.
Husain K; Centeno BA; Coppola D; Trevino J; Sebti SM; Malafa MP
Oncotarget; 2017 May; 8(19):31554-31567. PubMed ID: 28404939
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of HSP90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer.
Nagaraju GP; Zakka KM; Landry JC; Shaib WL; Lesinski GB; El-Rayes BF
Int J Cancer; 2019 Sep; 145(6):1529-1537. PubMed ID: 30801702
[TBL] [Abstract][Full Text] [Related]
36. Tumor-Penetrating Nanoparticles for Enhanced Anticancer Activity of Combined Photodynamic and Hypoxia-Activated Therapy.
Wang Y; Xie Y; Li J; Peng ZH; Sheinin Y; Zhou J; Oupický D
ACS Nano; 2017 Feb; 11(2):2227-2238. PubMed ID: 28165223
[TBL] [Abstract][Full Text] [Related]
37. The novel hypoxic cytotoxin, TX-2098 has antitumor effect in pancreatic cancer; possible mechanism through inhibiting VEGF and hypoxia inducible factor-1α targeted gene expression.
Miyake K; Nishioka M; Imura S; Batmunkh E; Uto Y; Nagasawa H; Hori H; Shimada M
Exp Cell Res; 2012 Aug; 318(13):1554-63. PubMed ID: 22472348
[TBL] [Abstract][Full Text] [Related]
38. The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells.
Ye Z; Li Y; Xie J; Feng Z; Yang X; Wu Y; Zhao K; Pu Y; Xu X; Zhu Z; Li W; Pan J; Chen W; Xing C
Anticancer Agents Med Chem; 2020; 20(12):1447-1458. PubMed ID: 32384038
[TBL] [Abstract][Full Text] [Related]
39. Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma.
Li Y; Zhao Z; Liu H; Fetse JP; Jain A; Lin CY; Cheng K
ACS Appl Mater Interfaces; 2019 Dec; 11(49):45390-45403. PubMed ID: 31769963
[TBL] [Abstract][Full Text] [Related]
40. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
